J&J boosts prostate cancer R&D with $650 million deal, Medivation drops
This article was originally published in Scrip
Executive Summary
Johnson & Johnson agreed to pay $650 million in cash for closely held Aragon Pharmaceuticals to get an experimental prostate cancer drug similar to Medivation's Xtandi.